U.S., Sept. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07845071) titled 'An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin' on Sept. 22.
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Pain
Intervention:
DRUG: Cebranopadol 400 ug
Participants receive Cebranopadol 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.
Recruitment Status: RECRUITING
Sponsor: Adneuris Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health...